1. Colloque de Veille Stratégique, Scientifique et Technologique 23-25 Octobre 2013 à Nancy Patents Analysis of induced Pluripotent Stem Cells (iPSC) Marine BODY – Claire LEVY – Thanusa PUVANENDRARAJAH / M2P – Droit de l’Immatériel et des Technologies de l’Information What are iPS cells? Research teams Inventors team for patents AUTHORSAUTHORSAUTHORSAUTHORS Pr. S Yamanaka WORLWORLDDMAPMAPWORLWORLDDMAPMAPD Geographical distribution of publications Countries which filled patents applications in US COMPANIESCOMPANIESCOMPANIESCOMPANIES Patents Patents applications Yamanaka team : - most important reseach team - works with no less than 18 people => diffuser of knowledges. Evolution of cluster classes during four periods: - Former classes have disappeared profits of the new classes. - In the center a few classes are regularly present. US patent classification is global, while the international classification is more accurate. Before 2006, the Carpenter & Xu team was the most important. After 2006 the Yamanaka’s team is appearing. The United States and Japan are the innovative countries. Other countries are focusing increasingly on the iPSC such as China, the countries of Western Europe... Only few countries apply for patents in the United States: Japan, Europe and India. California is the US state that contributes most to the progress in the field of iPSC. Five collaborations between different societies through the authors. Interesting alliance between a private company (Geron Corporation) and a public company (University of Edinburgh). An induced pluripotent stem cell (or iPS cell) is an adult cell that has been reprogrammed to behave like an embryonic stem cell (or ES cell). They have the same characteristics as embryonic cells without ethic problems. iPS cells in mice were created for the first time in 2006 by a japanese team directed by Shynia Yamanaka. In 2007, the experience was repeated on human skin cells. Since other production methods have been developed, either with new viral vectors, RNA or gene induction. In France, since 2004, such experimentations are allowed, provided they allow major therapeutic advances. - Various applications : cell therapy, basic research, pharmaceutic research… - iPS cells is a recent subject and booming given the numerous patents and publications - The topic of the year because, Shynia Yamanaka received the Nobel Prize 2012 for his researches. Director of Center for iPS Cell Research and Application. Professor at the Institute for Frontier Medical Sciences, Kyoto University. Semantic mesh - The Yamanaka’s team is still the most important - works with more 30 people directly and 9 indirectly Japan is still present. India stops to apply for patents and other countries appear like China, Europe, Saudi Arabia and Israel. In US, California is still present and Massachusetts appears. Inventors team for patents applications Countries which had patents in US Yamanaka works with two japanese universties (Kyoto and Tokyo) for patents applications. Some private companies (Cellular dynamics international, Asubio) work with public companies (Wisconsin alumni Research Foundation, Keio university) And some companies seem to work together, but in fact, they have been buy and change their name (Lifescan, Janssen Biotech, Centocor ortho biotech) IPS cells in number 1963 publications 52 patents 391 patents applications